18 completed, 3 terminated, 2 not yet recruiting, 2 recruiting. 10 Phase 3, 9 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 4.
Follow Inosine: new trials by email Literature Review of Inosine trials Research Report on Inosine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia Inhaled Nitric Oxide - Congenital Diaphragmatic Hernia, Pulmonary Hypertension | Phase 4 | Not yet recruiting | Asan Medical Center | 40 | 2025-11-01 | 2025-11-25 |
| De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use - Congenital Diaphragmatic Hernia | Phase 4 | Recruiting | The University of Texas Health Science Center, Houston | 600 | 2025-11-01 | 2026-08-18 |
| A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease Febuxostat, Inosine - Parkinson's Disease (PD) | Phase 1 | Recruiting | Fujita Health University | 24 | 2025-06-27 | 2025-09-12 |
| Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Completed | Fudan University | 10 | 2024-05-11 | 2025-07-18 |
| Cytoflavin in the Complex Rehabilitation of Stroke Patients Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Stroke | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 240 | 2023-06-30 | 2026-04-14 |
| Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis Remaxa, enteric-coated tablets, Remaxol, Placebo - Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 328 | 2023-05-27 | 2025-04-29 |
| Therapeutic Antioxidant Supplementation Inosine, IP6 - Superficial Siderosis | Not applicable | Not yet recruiting | Superficial Siderosis Research Alliance Inc. | 50 | 2023-05-01 | 2022-05-05 |
| Cytoflavin in Combination With Reperfusion in Stroke Patients Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control - Acute Stroke | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 200 | 2022-04-10 | 2023-03-20 | |
| Inosine Energy Expenditure Study Inosine, Placebo - Healthy Volunteers | Not applicable | Completed | University Hospital, Basel, Switzerland | 8 | 2022-02-28 | 2023-09-28 |
| Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Diabetic Neuropathies | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 216 | 2020-11-25 | 2023-01-27 |
| International Trial of Efficacy of Cytoflavin in Head Trauma Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Head Trauma,Closed | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 166 | 2020-11-22 | 2025-04-18 |
| Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemotherapy/targeting - Advanced Solid Tumor | Phase 2 / Phase 3 | Completed | Beijing Friendship Hospital | 172 | 2019-05-01 | 2023-04-12 |
| Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) Inosine, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Massachusetts General Hospital | 48 | 2017-10-01 | 2021-02-18 |
| Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest Nitric Oxide, Nitrogen - Heart Arrest, Out-Of-Hospital | Phase 2 | Terminated | Cameron Dezfulian | 57 | 2017-08-26 | 2022-04-25 |
| Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery Cytoflavin® solution, Cytoflavin® enteric-coated tablet, Placebo solution - Cognitive Dysfunction | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 200 | 2017-06-02 | 2023-01-31 |
| Remaxol® in Mechanical Jaundice of Non-malignant Origin Remaxol (succinate + methionine + inosine + nicotinamide), Ringer's Solution - Jaundice, Obstructive | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 342 | 2017-04-03 | 2020-07-14 |
| Remaxol® in Malignant Mechanical Jaundice Remaxol®, Ringer's Solution - Jaundice; Malignant | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 240 | 2017-04-03 | 2020-07-10 |
| Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen Inhaled Nitric Oxide 30mcg/kg IBW/hr - COPD, Pulmonary Hypertension | Early Phase 1 | Terminated | Bellerophon | 7 | 2016-10-01 | 2023-02-21 |
| Study of Urate Elevation in Parkinson's Disease, Phase 3 Inosine, Placebo - Parkinson's Disease | Phase 3 | Completed | Michael Alan Schwarzschild | 298 | 2016-06-01 | 2020-07-28 |
| A Food-Drug Interaction Study of Serum Urate After Oral Inosine Inosine - Healthy | Phase 1 | Completed | Michael Alan Schwarzschild | 18 | 2015-03-01 | 2017-03-29 |
Showing 20 of 27. Sign in to see all of them.
Hypertension, Pulmonary (4) · Parkinson Disease (3) · Amyotrophic Lateral Sclerosis (2) · Hernias, Diaphragmatic, Congenital (2) · Jaundice, Obstructive (2) · Stroke (2) · Brain Concussion (1) · Brain Injuries, Traumatic (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Cerebral Infarction (1) · Cholestasis, Intrahepatic (1) · Cognitive Dysfunction (1) · Coronavirus Infections (1) · Craniocerebral Trauma (1)
POLYSAN Scientific & Technological Pharmaceutical Company (8) · Massachusetts General Hospital (3) · Bellerophon (2) · Michael Alan Schwarzschild (2) · Asan Medical Center (1) · Beijing Friendship Hospital (1) · Cameron Dezfulian (1) · Fudan University (1) · Fujita Health University (1) · Mid-Atlantic Retina Consultations, Inc. (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · Superficial Siderosis Research Alliance Inc. (1) · The Parkinson Study Group (1) · The University of Texas Health Science Center, Houston (1) · Tufts Medical Center (1)
United States (11) · Russia (8) · China (2) · Belgium (1) · Japan (1) · Kazakhstan (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1)
Ashika Ahmed, MD (2) · Michael A Schwarzschild, MD, PhD (2) · Mikhail S. Bogomolov, MD, PhD (2) · Sabrina Paganoni, MD, PhD (2) · Alberto Ascherio, MD, DrPH (1) · Alexander V Savello, Prof (1) · Alexey Shmonin, Prof (1) · Cameron Dezfulian, MD (1) · David Oakes, PhD (1) · Dina R Khasanova, prof. (1) · Douglas C Hooper, PhD (1) · Eric A Macklin, PhD (1) · Hilary Koprowski, MD (1) · Igor A Strokov, Prof. (1) · Jennifer W Lee, MD, MS (1)
PMID 24366103, PMID 25162920, PMID 30631120, PMID 30837873, PMID 31484712, PMID 32871874, PMID 33769417, PMID 33942376, PMID 34519802, PMID 35119373, PMID 35680173, PMID 36865634, PMID 37702300, PMID 39251680, PMID 39267574, PMID 41551305
U01NS090259 (1)